News & Politics

PharmaTimes

pharmatimes.com

in-depth news, features and insights for the pharmaceutical and healthcare sectors

Articles100

NICE backs first systemic therapy for desmoid tumours

AbbVie wins EU approval for paediatric pJIA use

Investor horizons ahead of CPHI 2026

Lexeo expands Friedreich ataxia pipeline with Mantle deal

AC immune reports week-100 progress in VacSyn trial

Carvykti delivers five-year remissions in early myeloma

Grünenthal expands pain portfolio across Asia-Pacific

Heparegenix completes first darizmetinib treatment in phase 1b

Ethiopia, Norway and UK boost global epidemic preparedness

AstronauTx receives funding for Parkinson’s sleep research

Roche welcomes MHRA approval of Gazyvaro

Grünenthal acquires cancer medicine Stivarga

CHMP backs expanded use of teclistamab

Axoltis reports positive phase 2 data for NX210c

Sanofi and Cheplapharm forge new medicines partnership

Japan approves prefilled syringe for GSK’s shingles vaccine

EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201

Zerion partner files first EU application for Dispersome‑enabled product

Tozorakimab shows broad COPD benefit in new phase 3 data

Buried knowledge

Study highlights advance in influenza protection for older adults

NICE backs daratumumab quadruplet for transplant‑eligible myeloma

Teitur reports positive early data for Parkinson’s peptide TT‑P34

Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer

NICE backs ibrutinib regimen for untreated mantle cell lymphoma

Eric Muller

Andrew Fenny

Livdelzi accepted in Scotland for treatment of PBC

Khatera Alawi

Dr Mai-Britt Zocca

Building the future of clinical research around the patients it serves

Evolution

FDA approves Tivicay pd for youngest HIV patients

Connected trials

Koala trial doses first patient with novel KMA‑targeting CAR‑T

Heparegenix wins orphan drug status for darizmetinib

IMAVVY approved as first targeted therapy for wAIHA

Nxera partner gains acceptance for NBI‑1117567

Jemperli accepted for priority review by US FDA

Carterra supports AI‑designed protein study with HT-SPR platforms

Erasca secures FDA fast track for eras‑0015 in pancreatic cancer

Avulux gains FDA authorisation for migraine light‑sensitivity lens

Leqembi Iqlik launches in US for early Alzheimer’s

Lundbeck gains EU orphan status for anti‑ACTH antibody

AC Immune reports positive phase 1 data for ACI‑19764

VarmX begins global phase 3 trial of VMX C001

VarmX begins global phase 3 trial for VMX C001

FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough

MHRA sets out position on microbiome‑based medicinal products

US FDA accepts Teva’s new drug application for ecopipam

NICE backs Axhidrox for severe underarm sweating

Alzecure completes transaction with Lilly

EffRx to commercialise Testavan in Switzerland

Orpathys plus Tagrisso shows survival benefit in lung cancer

Definium reports positive results for anxiety treatment

Veppanu launch brings new option for advanced breast cancer

First patient treated in new heavy‑chain‑only antibody trial

Novo Nordisk and AWS form AI partnership to speed drug discovery

Kupando doses first patient in phase 1 trial

First-in-class house dust mite allergy treatment now available in Scotland

NHS backs new treatment option for cystinosis

Fridge‑free vaccine shows global potential

Lexeo wins FDA RMAT status for LX2020

EHP Awards 2027 open for entries

NICE backs new blood cancer regimens

Obsidian begins registration cohort for amsoki-cel

Entera Bio data selected for ASBMR plenary session

NHS backs delayed‑release treatment for cystinosis

Oblenio doses first patients in phase 1a autoimmune trial

BeOne Medicines secures UK innovation passport for HCC therapy

Sanofi’s MenQuadfi approved for EU infants

Qnovia licenses novel antimicrobial peptide

Lexeo wins FDA RMAT status for LX2020

Polpharma Biologics gains FDA and EMA review acceptances

Parsortix study shows promise for ADC target detection

Vista trial begins dosing in precision cancer vaccine study

Lynavoy recommended for EU approval by the CHMP

Atsena gains EMA orphan status for two gene therapies

J&J reports major survival gains with dual‑target myeloma regimen

OrbusNeich begins Japanese trial for drug‑coated balloon

Nezglyal receives positive CHMP opinion supporting treatment access for boys with cALD

Novogene Europe expands single‑cell sequencing capability in Cambridge

MAD World Summit 2026

GSK wins US approval for ROS1 lung cancer therapy

Lundbeck secures FDA Fast Track for narcolepsy drug

R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia

Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million

Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026

ViiV Healthcare to unveil new HIV treatment data at AIDS 2026

Ariane de Ganck

Jasper Therapeutics merges with Kira Pharmaceuticals

Bethany Mancilla

EpilepsyGTx and ClearPoint Neuro join forces on targeted therapy

Sophie Spencer

NICE backs finerenone for heart failure

EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC

FDA approves Leqembi Iqlik subcutaneous initiation dose for Alzheimer’s disease

SMC recommends VEOZA for moderate to severe menopausal vasomotor symptoms

SMC backs Columvi combination for second-line lymphoma treatment in Scotland

Pluripotent stem cell trial for Huntington’s disease